Literature DB >> 15123288

Ligand-selective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms.

Timothy R Geistlinger1, Andrea C McReynolds, R Kiplin Guy.   

Abstract

Ligand-dependent nuclear hormone receptor (NR) signaling requires direct interaction between NR and the steroid receptor coactivators (SRC). Herein we utilize a library of SRC2 peptidomimetics to select for specific inhibitors of the interaction of SRC2 with the two estrogen receptor (ER) isoforms, ERalpha and ERbeta, in the presence of three different ligands: 17beta-estradiol, diethylstilbesterol, and genistein. The pattern of inhibitor selectivity for each ER isoform varied depending upon which ligand was present, thus demonstrating that the ligands exert unique allosteric effects upon the surface of the SRC binding pocket. Several of the lead compounds are highly (>100-fold) selective for blocking the binding of SRC2 to ERalpha, in preference to ERbeta, in the presence of one ligand and therefore may prove useful for decoupling ERbeta signaling from ERalpha signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123288     DOI: 10.1016/j.chembiol.2004.01.016

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  5 in total

Review 1.  Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs).

Authors:  Terry W Moore; Christopher G Mayne; John A Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2009-11-20

2.  Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding.

Authors:  Alexander A Parent; Jillian R Gunther; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2008-09-12       Impact factor: 7.446

3.  A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines.

Authors:  Po-Shen Pan; Robert C Vasko; Stephanie A Lapera; Victoria A Johnson; Robert P Sellers; Chun-Chieh Lin; Chung-Mao Pan; Melinda R Davis; Veronica C Ardi; Shelli R McAlpine
Journal:  Bioorg Med Chem       Date:  2009-07-15       Impact factor: 3.641

4.  Synthesis and biological evaluation of guanylhydrazone coactivator binding inhibitors for the estrogen receptor.

Authors:  Andrew L LaFrate; Jillian R Gunther; Kathryn E Carlson; John A Katzenellenbogen
Journal:  Bioorg Med Chem       Date:  2008-10-07       Impact factor: 3.641

Review 5.  Androgen receptor: structure, role in prostate cancer and drug discovery.

Authors:  M H Eileen Tan; Jun Li; H Eric Xu; Karsten Melcher; Eu-leong Yong
Journal:  Acta Pharmacol Sin       Date:  2014-06-09       Impact factor: 6.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.